HCS Pharma, expert in cellular imaging & in vitro assay development for High Content Screening (HCS) & Analysis (HCA) has just acquired BIOMIMESYS® Technology, a biomimetic hydrogel scaffold based on biofunctionalized hyaluronic acid with extracellular matrix components for 3D cell culture.

If you have already used BIOMIMESYS® products, be aware that they will be available again in early 2018! If you do not know yet this technology, please let us know your interest.

Using BIOMIMESYS® Technology, HCS Pharma will also provide its expertise in HCS/HCA to evaluate the efficacy, mode of action, and safety of your therapeutic molecules on 3D cell models.

Ask us for a TC to know more about our services and products.

BIOMIMESYS® Plates’ assets:

  • Natural biofunctionnalized scaffold
  • Ready-to-use and easy to handle for highly reproducible experiments
  • Compatible with HTS & HCS
  • Use also for long term cultures & in vivo transplantation
  • Ease of cell retrieval, PCR & WB analysis

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

1 Comment

3D-printed minifactories at ETH Zurich | HCS-pharma · December 21, 2017 at 3:20 pm

[…] In HCS Pharma we are very interested by this evolution and we are working on our biomimetic hydrogel… […]

Leave a Reply